ITGA2B and endothelial dysfunction: Specifically, chronic cyclosporine A and, in a lesser way tacrolimus administration may result in platelet activation and endothelial dysfunction, as there is an increase in parameters of platelet degranulation (CD62P), activation (PAC-1), platelet leukocyte aggregate formation (CD41 et CD11b) and inflammatory response (soluble CD40 ligand) [23, 24].